Latest period
$29.97M
YoY change
-8.5%
5Y CAGR
+71.8%
Peak year (2024)
$28.90M
Latest annual
$26.43M
Stock-Based Compensation history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: $26.43M
Stock-Based Compensation growth chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -8.5%
Stock-Based Compensation history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | $26.43M | -8.5% | −$2.47M | ||
| 2024 | $28.90M | +51.5% | +$9.82M | ||
| 2023 | $19.08M | +34.1% | +$4.85M | ||
| 2022 | $14.23M | +81.7% | +$6.40M | ||
| 2021 | $7.83M | +344.0% | +$6.07M | ||
| 2020 | $1.76M | +4.1% | +$70.00K | ||
| 2019 | $1.69M | — | — |
- 2025$26.43M-8.5%
- 2024$28.90M+51.5%
- 2023$19.08M+34.1%
- 2022$14.23M+81.7%
- 2021$7.83M+344.0%
- 2020$1.76M+4.1%
- 2019$1.69M—
Stock-Based Compensation values are taken from Tango Therapeutics's reported cash flow statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Stock-Based Compensation at Tango Therapeutics (TNGX)
Stock-Based Compensation for Tango Therapeutics (TNGX): headline value $29.97M · YoY -8.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Tango Therapeutics (TNGX) most recent annual stock-based compensation stands at $26.43M (2025) – declined 8.5% year-over-year.
Through 2020–2025 (5 years), Tango Therapeutics stock-based compensation delivered a +71.8% annualised rate; with mixed annual results across the window.
The record annual stock-based compensation stands at $28.90M, reached in 2024; the historical low of $1.69M was recorded in 2019.
Tango Therapeutics Stock-Based Compensation by Year
Tango Therapeutics Stock-Based Compensation 2025: $26.43M
Tango Therapeutics stock-based compensation in 2025 was $26.43M, declined 8.5% below 2024.
Tango Therapeutics Stock-Based Compensation 2024: $28.90M
2024's stock-based compensation for Tango Therapeutics came in at $28.90M, surged 51.5% from 2023. This figure represents the highest annual value in the available history.
Tango Therapeutics Stock-Based Compensation 2023: $19.08M
Tango Therapeutics posted stock-based compensation of $19.08M in 2023, surged 34.1% from 2022.
Tango Therapeutics Stock-Based Compensation 2022: $14.23M
In 2022, Tango Therapeutics reported stock-based compensation of $14.23M, surged 81.7% from 2021.
Tango Therapeutics Stock-Based Compensation 2021: $7.83M
Tango Therapeutics stock-based compensation in 2021 was $7.83M.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by Stock-Based Compensation
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest stock-based compensation
| $1.35B | |
| $971.00M | |
| $955.00M | |
| $626.00M | |
| $0.00 | |
| $0.00 | |
| $0.00 | |
| $0.00 |
- $1.35B
- $971.00M
- $955.00M
- $626.00M
- $0.00
- $0.00
- $0.00
- $0.00
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation